FAS and colorectal carcinoma: Figure 5 showed the anticancer activity of EGCG against CRC via P53, BAX, Fas, DR5, caspase 3/8/9 upregulation, apoptosis induction, Bcl‐2, Bcl‐xL suppression, and NF‐κB, P13K/Akt downregulation.